InVivo Therapeutics Holdings Corp, a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, announces that it has completed enrollment in the INSPIRE 2.0 Study for patients with acute spinal cord injury.
The 20-patient study is a randomized, controlled trial featuring 10 subjects in each study arm, designed to enhance the existing clinical evidence for the Neuro-Spinal Scaffold™ from the Company’s INSPIRE 1.0 study.
“Reaching full enrollment in our INSPIRE 2.0 study is a significant advancement in our research and development efforts towards a potential treatment for spinal cord injury,” said Richard Toselli, MD, InVivo’s President and Chief Executive Officer. “We’re grateful to the study participants, as well as the clinicians, investigators, and staff who have worked relentlessly to make this possible, and of course to our team at InVivo. We’re very excited to be continuing towards our goal of serving this patient population and expect to present topline data from the study in Q1 of 2023.”
Kee Kim, MD, Professor and Chief of Spinal Neurosurgery at UC Davis, Sacramento, Calif, and a Principal Investigator in the INSPIRE 2.0 Study, stated “Completing patient enrollment in the INSPIRE 2.0 Study is a major milestone for the spinal cord injury community, and I am pleased to have had the opportunity to help improve potential treatment options for this underserved patient population.”
[Source(s): InVivo Therapeutics, Business Wire]
Related Content:
Study Describes InVivo’s CONTEMPO Registry Data
